Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
The filing discloses the election of two new directors, Frederick J. Crawford and Paul J. Smith, to Humana's Board effective July 28, 2026, expanding the board from eleven to thirteen members. Both individuals are described as independent directors and will receive RSU grants under the company's director compensation program. This is a clear executive appointment event, material to investors as board composition affects governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Peter Carter, age 63 and currently President of Delta Air Lines, was elected to Xcel Energy's Board of Directors effective July 29, 2026, and appointed to the Audit Committee and Governance, Compensation and Nominating Committee. The filing explicitly states the Board determined Mr. Carter is independent and meets Nasdaq independence requirements. This is a clear director appointment under Item 5.02(d), and the addition of an experienced executive from a major corporation to the board is material to investors assessing governance quality and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
Shailesh Jejurikar has been appointed as Chairman of the Board effective August 1, 2026, in addition to his existing role as President and CEO, representing a significant governance change at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
V.F. Corporation appointed Abhishek Dalmia as Executive Vice President and Chief Financial Officer effective August 1, 2026, with expanded responsibilities to also serve as Chief Operating Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-29
Item 5.02
Andreas W. Mattes was appointed as a director and chair of the Compensation Committee effective July 28, 2026. The appointment brings significant semiconductor industry experience, including prior CEO roles at Coherent and Diebold Nixdorf, and includes compensation terms of an $80,000 annual retainer plus a $500,000 initial RSU grant.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
Jack Henris was appointed as Chief Executive Officer and Director of Dakota Gold Corp., effective August 18, 2026, with compensation terms including a $360,000 base salary, 75% discretionary bonus, and $630,000 long-term incentive compensation. This appointment represents a significant leadership transition at the development-stage mining company as it prepares for the Richmond Hill Gold Project development phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Keith Schwarz was appointed as an independent director and audit committee member effective July 29, 2026, with compensation including an annual cash retainer of $100,000, audit committee retainer of $15,000, and a $150,000 equity grant.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
EX-99.1
The press release announces the appointment of Depesh Narotam as an independent director of XORTX Therapeutics Inc., effective July 27, 2026. He has also been appointed to the Compensation, Governance and Nominating Committee. This is a clear executive/board appointment disclosure, material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-29
Item 5.02
The filing discloses the appointment of two new directors, Sharon L. O'Keefe and Thomas A. West, to the Board effective July 28, 2026, following an increase in authorized board size from seven to nine directors. While the section also mentions reclassifications of existing directors Burke and Taylor for rebalancing purposes, the principal disclosed action centers on the election of two new directors with specified committee assignments and compensation arrangements. This is material as it represents a change in board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
The Board appointed Kimberly Hawley as Interim Chief Financial Officer effective July 6, 2026, with an employment agreement providing $250,000 annual base salary and a $50,000 restricted stock grant. While the disclosure includes compensatory details, the principal disclosed action is the appointment of a named executive to a C-suite officer role, making this an executive appointment event. The appointment of an interim CFO is material to investors assessing the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Jeffrey Harris was appointed to the Board of Directors as a Class II director effective July 26, 2026, filling a vacancy. While Harris previously served as CEO and founder of SpringBig before his resignation on March 31, 2025, the principal disclosed action here is his appointment to the Board. This is a material governance event involving a significant figure in the company's history returning to a leadership position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Three directors—Melvin D. Lindsey, Richard W. Cook, and Christopher Heatherly—were appointed to the Board effective July 27, 2026, in connection with the IPO, with assignments to the Audit, Compensation, and Corporate Governance and Nominating committees.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
EX-99.1
The press release announces the re-appointment of Marco Leone to Nuvini's Board of Directors as an independent director, effective July 27, 2026. The appointment is material because it directly addresses a Nasdaq compliance issue: the Company had fallen out of compliance with Nasdaq Listing Rule 5605 (requiring a minimum of three independent directors on the audit committee), and Leone's election as an independent director restored that compliance. This is a governance event with direct regulatory and operational significance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
EX-99.1
Marcelo Ken Suhara was appointed on July 27, 2026, as Chair Member of Afya's Audit, Risks and Ethics Committee, succeeding João Paulo Seibel de Faria who passed away. This is a material governance appointment to a key committee leadership role overseeing audit and risk matters, affecting the composition and leadership of the company's audit oversight function.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-29
Item 5.02
Sonos appointed Chris Shackelton as a Class II director effective July 28, 2026, increasing the board size from ten to eleven members. Shackelton is described as a long-term investor with significant experience in strategy, financial markets, and capital allocation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Alp E. Can was appointed Chief Operating Officer of the Federal Home Loan Bank of Atlanta, effective August 10, 2026, representing a material promotion to a senior C-suite position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
The filing announces the appointment of Jonathan M. Collins as Executive Vice President and Chief Financial Officer effective August 10, 2026, along with the concurrent appointment of Todd W. Fister as President and Chief Operating Officer. While the disclosure includes compensatory details (base salary of $775,000, equity awards totaling $4.5 million, and a $500,000 sign-on bonus), the principal disclosed action is the appointment of these executives to new roles. The filing also mentions retention awards to other named executive officers, but these are secondary to the primary executive appointments. This is material as it involves changes to senior leadership positions critical to the company's operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-29
Item 5.02
The Company appointed three executives and directors effective July 31, 2026: Zoran Milošević as Chief Executive Officer, William Scott as Chief Financial Officer (transitioning from Interim CEO while remaining Chairman), and Michael Prescott as an Independent Director, as part of a Board-led succession process to drive the next stage of global expansion.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-07-29
EX-99.1
The exhibit announces the appointment of David Sturgeon as Chief Financial Officer of RedCloud Holdings plc, effective August 1, 2026. This is a clear executive appointment of a named officer to a C-suite role at a recently-listed public company. The disclosure emphasizes his extensive experience at Nasdaq-listed companies and his expertise in SEC reporting, investor relations, and corporate governance — all material to a recently-listed, high-growth company's governance and financial leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-29
Item 5.02
Sheila Gujrathi, M.D., was appointed to Processa's Board of Directors effective immediately after the merger closing on July 28, 2026, bringing extensive biopharmaceutical industry experience as part of the leadership changes resulting from the Vidya acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Doug Stiles was appointed President of Silver Bow Mining Corp. effective July 27, 2026, having previously served as Vice President of Regulatory and External Affairs since February 2026. The appointment is material given his 25+ years of mining experience and critical role in advancing the company's flagship Rainbow Block Project.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
David Smith, a current director, was appointed to serve as Interim Chief Financial Officer effective July 27, 2026, following the placement of recently appointed CFO Jason Knoblauch on paid leave due to pending litigation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
The filing discloses both a director departure (David Barse's resignation on July 27, 2026) and a director appointment (Daniel Lewis elected to the Board on July 27, 2026, effective immediately). While both events are disclosed, the substantive focus and forward-looking impact center on the appointment of Lewis as a new director with a term through the 2027 annual meeting. The departure is explicitly stated as non-contentious and unrelated to disagreements. The appointment is the material governance action that affects board composition going forward.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
The filing announces the appointment of Olaf Koch as Non-Executive Director of Vodafone Group Plc effective 27 July 2026, following shareholder approval at the 2026 Annual General Meeting. Koch will also join the Remuneration Committee and ESG Committee effective 1 August 2026. This is a clear executive appointment disclosure under the governance domain, material to investors as it affects board composition and committee membership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
James S. Filter, the Company's President and Chief Executive Officer, was appointed as a director of Schneider National, Inc. effective July 27, 2026. The Board increased its size from ten to eleven directors to accommodate this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-07-29
Item 5.02
Michael Easton was appointed Executive Vice President & Chief Financial Officer effective August 8, 2026, succeeding Jonathan Collins. Easton was promoted internally from Senior Vice President and Chief Accounting Officer, bringing 25+ years of financial expertise. Matthew Lisowski was simultaneously appointed Senior Vice President, Chief Accounting Officer, also effective August 8, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Chandu Thota was appointed as a Class II director of Dynatrace effective July 27, 2026, increasing the Board size from 10 to 11 directors. Thota brings 20+ years of experience in AI, cloud infrastructure, and enterprise software from leadership roles at Google and Microsoft, and is determined to be independent by the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Core Scientific appointed Mark W. Adams to its Board of Directors, effective July 29, 2026. Adams brings over 25 years of technology sector experience, including prior roles as President and CEO of Penguin Solutions and President of Micron Technology, and meets independence requirements under Sarbanes-Oxley and Nasdaq listing standards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-28
Item 5.02
The Board appointed John F. Ghingo as President and Chief Executive Officer effective October 26, 2026, representing a material promotion from his current role as President. While the disclosure also includes compensatory arrangements (salary increase to $1.28 million, long-term incentive target of $6.8 million, and severance provisions), the principal disclosed action is Ghingo's appointment to the CEO role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Ms. Kristen J. Pederson as a new director to NPK International's Board, effective July 28, 2026, with concurrent appointment to the Audit, Compensation, and Nominating and Corporate Governance Committees. The principal disclosed action is a person taking a role (director and committee member), making this an exec_appointment. The disclosure includes her extensive background in corporate governance, board experience, and compensation details (pro-rated cash and equity retainers), which are material to investors assessing board composition and governance strength.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
Martin Madaus was elected as a director of Haemonetics Corporation, effective July 24, 2026, and appointed to the Audit Committee and Governance and Compliance Committee.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-28
EX-99.1
The exhibit announces the appointment of Mr. Yanjun Sun as an independent director of H World's Board, effective July 28, 2026. This is a clear executive/governance appointment disclosing a named individual taking a director role. The candidate's substantial background in investment, M&A, and business operations at major firms (Jardine Matheson, TPG Capital, Goldman Sachs) and current board positions at other public companies makes this material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of two independent directors, Emily Chiu and Leslie Storms, to Covista's Board effective August 17, 2026. The principal disclosed action is the appointment of these individuals to board positions, supported by detailed biographical information highlighting their executive experience in technology, fintech, healthcare delivery, and medtech. While compensation terms are also disclosed, the core event is the appointment itself, making this an exec_appointment rather than exec_compensation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-28
Item 5.02
The filing discloses both departures (Schroeder and Pampalone retiring) and multiple appointments (Shuman as CTO, Woytera, Materazzo, and Müller to expanded roles). While both events occur, the appointments of named executives to significant leadership positions—particularly Eric Shuman's appointment as Chief Technology Officer effective January 1, 2027, and the expanded responsibilities of three other global leadership team members—constitute the principal disclosed actions. The filing emphasizes the succession planning and new leadership structure, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The Board of Directors elected Evan Yu to the Board effective August 1, 2026, as an independent director. Yu is a seasoned global semiconductor executive with prior experience at Diodes (2008–2023) and other major semiconductor firms, bringing deep expertise in power products and international operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-07-28
Item 5.02
Ashland appointed two new independent directors, Peter Thomas (former CEO of Ferro Corporation) and Allen Spizzo (former CFO of Hercules Incorporated), effective July 27, 2026, as part of a Cooperation Agreement with activist stockholder Ancora Holdings Group, LLC. The appointments include roles on a newly formed Capital Allocation Advisory Committee and reflect material board refreshment driven by shareholder engagement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 7.01
The filing discloses the appointment of Bipin Dalmia, PhD, MBA as Chief Business Officer of Relmada Therapeutics, effective July 28, 2026. The press release emphasizes his nearly three decades of biopharmaceutical leadership, his expertise in NMIBC and intravesical therapies, and his direct reporting relationship to the CEO. This is a material executive appointment to a senior officer role at a clinical-stage biotechnology company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Paul Strickland as Chief Financial Officer and director (effective July 22, 2026), Kyoung Tak Kim as independent director and audit committee member, and Wang Jo Cha as independent director and compensation committee member. While Jung Min Lee's departure as acting CFO is mentioned, the principal disclosed action centers on three new executive and board appointments with detailed biographical information and executed offer letters and indemnification agreements, making this clearly an exec_appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
Gary Greenberg was appointed to the Board of Directors on July 23, 2026 in connection with the IPO and was also appointed as chair of the Audit Committee, establishing the governance structure of the newly public SPAC.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-28
EX-99.1
The exhibit announces the appointment of Mr. Sanjay E. Sarma as a Non-Executive Director of Ferrovial following Board recommendation, with the appointment expected to be submitted to the next Shareholders Meeting. While the exhibit also discloses the resignation of Mr. José Fernando Sánchez-Junco, the principal disclosed action is the appointment of a new director to fill a vacancy, making exec_appointment the primary classification. The appointment of a new board member with significant technology and innovation expertise is material to investors assessing board composition and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
David Marshall Nissman was appointed to the Board of Directors and the Audit Committee effective July 24, 2026. Daniel Snyder resigned as Director on the same date for personal reasons.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-07-28
EX-99.1
The exhibit announces the appointment of Brendan P. O'Grady as Chief Executive Officer of Nasus Pharma, effective July 27, 2026, succeeding Dan Teleman. This is a material executive appointment of a named officer to a principal leadership role. The disclosure includes O'Grady's extensive qualifications (35 years of pharma experience, prior CEO roles at Teva USA and Assertio Holdings) and the Board's rationale for the appointment, making it a clear and material governance event affecting the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 8.01
Ryan Manning's appointment as Chief Product and Technology Officer, effective August 10, 2026, is a material executive appointment. The role oversees global product and engineering functions, making it a senior leadership position that would affect investor assessment of the company's operational leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
ZipRecruiter appointed Carmen Chan as Chief Financial Officer effective August 17, 2026, with compensation including $500,000 base salary, $100,000 minimum bonus, $200,000 onboarding bonus, and 650,000 RSUs. Dave Travers will cease serving as interim CFO upon her assumption of the role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
Bicara Therapeutics appointed Jeremy Bender, Ph.D. (former CEO of Day One Biopharmaceuticals) and Christy Oliger (former SVP of Oncology at Genentech) as directors on July 28, 2026, bringing 20+ and 30+ years of biotech and biopharmaceutical experience respectively. The appointments include committee assignments and formation of a new Launch Readiness Committee to support the company's commercialization efforts for its lead program ficerafusp alfa.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-28
Item 5.02
The disclosure centers on the Board's appointment of Joseph Alvarado as incoming Chairman of the Board, effective October 28, 2026, to succeed William M. Lambert. While Lambert's retirement is also disclosed, the principal action announced is Alvarado's appointment to the Chairman role. The press release and Item 5.02 emphasize the appointment and Alvarado's qualifications and experience, making this an exec_appointment event. This is material as it involves a change in the company's top governance leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Anya Hamill as Chief Financial Officer effective September 8, 2026, with detailed compensation terms including base salary of $450,000, bonus structure, equity grants (37,500 RSUs and 37,500 options), and a $100,000 sign-on bonus. While the filing also mentions Brian Dostie's resignation as Interim CFO, the principal disclosed action centers on the appointment of a new CFO to a key executive role, making this an exec_appointment event. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Nick Stead as Chief Financial Officer effective January 1, 2027, along with his designation as principal financial officer and principal accounting officer. While the filing also mentions Tim Bixby's transition from CFO to Board member, the principal disclosed action centers on Stead's appointment to the CFO role, a named executive officer position. The appointment of a new CFO is material to investors assessing the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of five executive officers effective July 27, 2026: Alexandra Renner (Chief Product Officer), John Hanson (Chief of Staff), Vivek Narayanadas (General Counsel and Corporate Secretary), Erik Lassen (Senior Vice President of Engineering), and Michael Dixon (Vice President of Accounting and Controller/Principal Accounting Officer). While some appointees were already serving in these roles informally, the Board's formal appointment of these individuals to executive officer positions on July 22, 2026 constitutes a material governance event affecting the registrant's leadership structure and disclosure obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
Terrestrial Energy Inc. appointed Kathryn McCarthy to its Board of Directors effective July 22, 2026. McCarthy brings substantial nuclear industry expertise, including leadership of the US ITER Project and senior roles at national laboratories, strengthening the company's governance in advanced reactor development.
View raw filing on EDGAR →